scholarly journals The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients

2009 ◽  
Vol 72 (07) ◽  
pp. 5-14 ◽  
Author(s):  
J. Herberth ◽  
M.-C. Monier-Faugere ◽  
H.W. Mawad ◽  
A.J. Branscum ◽  
Z. Herberth ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Bone Turnover ◽  
Intact Parathyroid Hormone

The Circadian Rhythm of Intact Parathyroid Hormone-(1–84): Temporal Correlation with Prolactin Secretion in Normal Men

1990 ◽  
Vol 71 (6) ◽  
pp. 1556-1560 ◽  
Author(s):  
F. C. LOGUE ◽  
W. D. FRASER ◽  
D. ST. J. O'REILLY ◽  
D. A. CAMERON ◽  
A. J. KELLY ◽  
...  
Keyword(s):  
Circadian Rhythm ◽  
Parathyroid Hormone ◽  
Temporal Correlation ◽  
Prolactin Secretion ◽  
Intact Parathyroid Hormone ◽  
Normal Men

scholarly journals No association between vitamin D deficiency and parathyroid hormone, bone density and bone turnover in a large cohort of HIV-infected men on tenofovir

2014 ◽  
Vol 17 ◽  
pp. 19568 ◽  
Author(s):  
Amanda Samarawickrama ◽  
Sophie Jose ◽  
Caroline Sabin ◽  
Karen Walker-Bone ◽  
Martin Fisher ◽  
...  
Keyword(s):  
Vitamin D ◽  
Parathyroid Hormone ◽  
Bone Density ◽  
Bone Turnover ◽  
Vitamin D Deficiency ◽  
Large Cohort

Effect of a protease inhibitor on in vitro stability of intact parathyroid hormone

2003 ◽  
Vol 40 (2) ◽  
pp. 188-190 ◽  
Author(s):  
N. R. Anderson ◽  
J. Nicholas ◽  
M. R. Holland ◽  
R. Gama
Keyword(s):  
Parathyroid Hormone ◽  
Protease Inhibitor ◽  
Protease Activity ◽  
Intact Parathyroid Hormone ◽  
In Vitro Degradation ◽  
Glass Tubes ◽  
Edta Plasma ◽  
In Vitro Stability ◽  
Baseline Sample

Background: We investigated whether increased protease activity explains the increased in vitro degradation of intact parathyroid hormone (iPTH) observed in serum when compared to EDTA plasma. Methods: Pre-dialysis blood samples for iPTH were taken from 11 patients with chronic renal failure and collected into plain glass tubes, tubes containing 200 KIU/mL aprotinin (a protease inhibitor) and EDTA tubes. All sample aliquots were separated at 20 min, 1 h, 2 h, 4 h, 8 h and 24 h post collection. Results: Over 24 h, iPTH concentrations remained unchanged in EDTA tubes. iPTH concentrations were significantly lower in both plain tubes ( P < 0·01) and aprotinin tubes ( P < 0·001) at 24 h when compared to the baseline sample (20 min). At 24 h, iPTH concentrations in EDTA tubes were higher than in plain tubes ( P < 0·001) and aprotinin tubes ( P < 0·01). The addition of aprotinin to plain tubes significantly reduced the degradation of iPTH ( P < 0·05) at 24 h. Conclusion: Aprotinin significantly reduces the in vitro degradation of iPTH in plain tubes at 24 h from 24·7% to 9·6%. We suggest that increased protease activity contributes to the decline in serum iPTH over time. As this is observed in serum and not plasma it suggests that the increased protease activity may be due to the clotting process.

scholarly journals Serum intact parathyroid hormone levels in cats with chronic kidney disease

2013 ◽  
Vol 33 (2) ◽  
pp. 229-235 ◽  
Author(s):  
Luciano H. Giovaninni ◽  
Marcia M. Kogika ◽  
Marcio D. Lustoza ◽  
Archivaldo Reche Junior ◽  
Vera A.B.F. Wirthl ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Stage Iv ◽  
Control Group ◽  
Intact Parathyroid Hormone ◽  
Acid Base ◽  
Acid Base Status ◽  
Serum Ionized Calcium ◽  
Progression Of Renal Disease

Chronic kidney disease (CKD) is frequently observed in cats and it is characterized as a multisystemic illness, caused by several underlying metabolic changes, and secondary renal hyperparathyroidism (SRHPT) is relatively common; usually it is associated with the progression of renal disease and poor prognosis. This study aimed at determining the frequency of SRHPT, and discussing possible mechanisms that could contribute to the development of SRHPT in cats at different stages of CKD through the evaluation of calcium and phosphorus metabolism, as well as acid-base status. Forty owned cats with CKD were included and divided into three groups, according to the stages of the disease, classified according to the International Renal Interest Society (IRIS) as Stage II (n=12), Stage III (n=22) and Stage IV (n=6). Control group was composed of 21 clinically healthy cats. Increased serum intact parathyroid hormone (iPTH) concentrations were observed in most CKD cats in all stages, and mainly in Stage IV, which hyperphosphatemia and ionized hypocalcemia were detected and associated to the cause for the development of SRHPT. In Stages II and III, however, ionized hypercalcemia was noticed suggesting that the development of SRHPT might be associated with other factors, and metabolic acidosis could be involved to the increase of serum ionized calcium. Therefore, causes for the development of SRHPT seem to be multifactorial and they must be further investigated, mainly in the early stages of CKD in cats, as hyperphosphatemia and ionized hypocalcemia could not be the only factors involved.

Intact parathyroid hormone levels and primary hyperparathyroidism

2017 ◽  
pp. 1-5 ◽  
Author(s):  
Haidar Al-Hraishawi ◽  
Peter J. Dellatore ◽  
Xinjiang Cai ◽  
Xiangbing Wang
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Intact Parathyroid Hormone ◽  
Hormone Levels

scholarly journals Management of urolithiasis associated with tuberous sclerosis complex

2019 ◽  
Author(s):  
Takashi Hatano ◽  
Yu Imai ◽  
Kei-ichiro Mori ◽  
Jun Moritake ◽  
Katsuhisa Endo ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Specific Gravity ◽  
Tuberous Sclerosis ◽  
Tuberous Sclerosis Complex ◽  
Urine Specific Gravity ◽  
Intact Parathyroid Hormone ◽  
Urine Ph ◽  
Extracorporeal Shock Wave ◽  
Increased Risk ◽  
Significant Difference

Abstract The most common renal symptoms of tuberous sclerosis complex (TSC) are angiomyolipomas (AMLs) and renal cysts; however, some patients with TSC also develop urolithiasis. In this study, we evaluated the incidence, risk factors and clinical courses of TSC-associated urolithiasis. We analyzed a total of 102 patients who met the diagnostic criteria for TSC, of whom 15 (14.7%) had urolithiasis. We compared urinary specific gravity, urine pH, serum calcium, intact parathyroid hormone and the use of antiepileptic agents of the urolithiasis and non-urolithiasis groups. The urine specific gravity and urine pH were higher in the urolithiasis group than in the non-urolithiasis group (P = 0.005, P = 0.042, respectively). No significant difference was found between the two groups with regard to the serum corrected calcium and intact parathyroid hormone levels. The antiepileptic drugs topiramate and zonisamide were more frequently administered to the urolithiasis group than the non-urolithiasis group (P <0.001, P = 0.039, respectively). Four patients in the urolithiasis group underwent surgery. Three patients could not receive extracorporeal shock wave lithotripsy due to the risk of bleeding from the AML, and therefore underwent transurethral lithotripsy. If urolithiasis is comorbid with TSC-associated AML, the treatment options are more limited in cases with multiple AMLs around the stone due to an increased risk of hemorrhage. Prevention and early detection of urolithiasis are beneficial to patients with TSC.

Sign in / Sign up

Export Citation Format

Share Document